WHO ICTRP trial
Nivolumab in renal transplant recipients with cancer
ACTRN12617000741381 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12617000741381 |
|---|---|
| Public title | Nivolumab in renal transplant recipients with cancer |
| Scientific title | Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study. |
| Primary sponsor | Central Northern Adelaide Local Health Network, Royal Adelaide Hospital |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Renal Transplant;Cancer; Renal Transplant Cancer;Renal and Urogenital - Kidney disease;Cancer - Any cancer |
| Interventions | This Phase 1, multicenter, open label, two tier safety study is designed to assess the safety of standard dosing of Nivolumab in kidney transplant patients with pretreated incurable cancer or defined metastatic solid tumours. Patient… |
| Registration date | May 22, 2017 |
| Target size | 30 |
| Secondary IDs | Protocol CA209-993ISR |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: